Mastering AAV production: best practices for small to large-scale manufacturing success and reduced development times

Cell & Gene Therapy Insights 2024; 10(8), 1101–1119

DOI: 10.18609/cgti.2024.126

Published: 1 October
Innovator Insight
Emily Jackson-Holmes

The article discusses the optimization and scalability of AAV production, highlighting the primary challenges in small-scale AAV production, such as long lead times, low titers, and high costs. The article further discusses the scalability of AAV production to commercial scales while maintaining performance and quality, and it presents best practices for achieving high AAV titers with a particular focus on the transfection step and optimizing plasmid ratios.